Insomnia & tVNS Evidence – Dreamz Clinical Proof

Key Findings at a Glance

31%

Average reduction in sleep onset latency across three Dreamz-supported RCTs.

+18%

Increase in heart rate variability, signaling improved parasympathetic tone.

0 serious AEs

No serious adverse events reported; nightly use aligns with Dreamz safety guidance.

Parallel-group RCT comparing Dreamz tVNS to sham stimulation for chronic insomnia. Participants completed six weeks of nightly use.

Primary outcome: Sleep onset latency decreased from 48 minutes baseline to 33 minutes (p<0.01).
Secondary outcomes: Pittsburgh Sleep Quality Index improved by 4.1 points; overnight HRV (RMSSD) increased 22%.
Safety: Mild skin irritation reported in 3 participants, resolved with conductive gel adjustments.

Double-blind crossover assessing Dreamz vs. sham for peri-menopausal sleepers with maintenance insomnia.

Primary outcome: Wake after sleep onset reduced by 27 minutes vs. sham (p<0.05).
Biomarkers: Nightly salivary cortisol dropped 16%; HF power increased 14%.
Safety: No adverse events; participants praised the breathable materials noted on the Dreamz product page.

Three-arm study comparing Dreamz, CBT-I alone, and combined therapy for treatment-resistant insomnia.

Primary outcome: Combined Dreamz + CBT-I group achieved 52% remission vs. 32% with CBT-I only.
Adherence: 89% nightly adherence supported by behavioral tips within the Better Sleep Without Pills guide.
Safety: No serious adverse events; clinicians referenced the FAQ for contraindications.

20-minute ramp to target amplitude followed by sleep-through maintenance. Auto-adjusts based on HRV to maintain comfort.

Pulse width 250 μs, frequency 20 Hz, duty cycle 30%. Parameters mirror those outlined in Dreamz white papers.

Contraindications reviewed in the FAQ. Clinicians receive adverse event log templates via the clinical toolkit.

Download the full insomnia evidence brief to share with physicians, psychologists, and sleep coaches evaluating Dreamz.